Autonomous artificial intelligence for diabetic eye disease increases access and health equity in underserved populations.
PubMed ID: 39039218 Author(s): Huang JJ, Channa R, Wolf RM, Dong Y, Liang M, Wang J, Abramoff MD, Liu TYA. Autonomous artificial intelligence for diabetic eye disease increases access and health equity in underserved populations. …
Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration.
PubMed ID: 39025435 Author(s): Keenan TDL, Agron E, Keane PA, Domalpally A, Chew EY; AREDS and AREDS2 Research Groups. Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration. …
Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration.
PubMed ID: 39025435 Author(s): Keenan TDL, Agron E, Keane PA, Domalpally A, Chew EY; AREDS and AREDS2 Research Groups. Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration. …
Dipeptidyl peptidase 4 inhibitors, sodium glucose cotransporter 2 inhibitors, and glucagon-like peptide 1 receptor agonists do not worsen diabetic macular edema.
PubMed ID: 39018897 Author(s): Phu A, Banghart M, Bahrainian M, Liu TYA, Wolf RM, Channa R. Dipeptidyl peptidase 4 inhibitors, sodium glucose cotransporter 2 inhibitors, and glucagon-like peptide 1 receptor agonists do not worsen diabetic …
Quantifying Geographic Atrophy in Age-Related Macular Degeneration: A Comparative Analysis Across 12 Deep Learning Models.
PubMed ID: 39046755 Author(s): Safai A, Froines C, Slater R, Linderman RE, Bogost J, Pacheco C, Voland R, Pak J, Tiwari P, Channa R, Domalpally A. Quantifying Geographic Atrophy in Age-Related Macular Degeneration: A Comparative …